Phase 2 Relapsed and/or Refractory Multiple Myeloma Clinical Trials
4 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–4 of 4 trials
Recruiting
Phase 2
18F-Fluciclovine PET/CT in Multiple Myeloma
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)60 enrolled1 locationNCT06103838
Recruiting
Phase 1Phase 2
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)54 enrolled1 locationNCT06876142
Recruiting
Phase 1Phase 2
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Relapsed and/or Refractory Multiple Myeloma
OriCell Therapeutics Co., Ltd.83 enrolled5 locationsNCT06182696
Recruiting
Phase 1Phase 2
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
Beijing InnoCare Pharma Tech Co., Ltd.80 enrolled6 locationsNCT05719701